Smith & Nephew launches ALLEVYN Life

Smith & Nephew launches ALLEVYN Life

20 July, 2012
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announced the launch of ALLEVYN◊ Life - an innovative new advanced wound management dressing. ALLEVYN Life is the latest product innovation to address the findings of new research into the real life concerns of patients living with wounds.

“We are very excited about the ALLEVYN Life product and the impact it can have on reducing the human and economic cost of wounds. Many people are affected by wounds and these patients often have significantly impaired wellbeing, as well as concerns around how others will perceive them. This poses significant challenges for patients, clinicians, payers and the healthcare facilities that care for them.” said Roger Teasdale, President of Smith & Nephew Advanced Wound Management.

“With the ever increasing pressure on healthcare budgets, today more than ever, it is important to ensure new products deliver clinical improvements that also translate into improved economic outcomes. The development of ALLEVYN Life has been driven by these challenges faced by our customers and the significant body of evidence indicating that delivering patient centred care leads to improvements in patient concordance, clinical outcomes and, as a result, improved economic outcomes. ALLEVYN Life has been launched to help deliver improved patient outcomes whilst allowing healthcare systems to work within existing woundcare budgets”, added Teasdale.

Over the last 3 years Smith & Nephew has undertaken extensive international ethnographic research across a number of countries, with patients and clinicians, to gain an in-depth understanding of how living with a wound can affect patient wellbeing and how dressing design can improve the patient and clinician experience whilst reducing the economic costs. This ethos is now embedded in our product development processes and has underpinned many of our recent launches, including ALLEVYN Life.

The research highlighted how people living with wounds are often concerned about issues like possible leakage of wound fluid, the unsightly appearance of exudate and wound odour, and in particular how this may affect their social interactions. There was also concern about the potential damage from knocks and bumps of everyday living and how this might restrict their ability to go about their daily lives. These insights helped validate that improving patient wellbeing is fundamental to reducing the economic cost of woundcare. ALLEVYN Life offers unique benefits that help deliver this and is a significant advancement in preventing wounds diminishing the quality of life of hundreds of thousands of patients every year. ALLEVYN Life will now be rolled out globally over the coming months.

About ALLEVYN Life:-

ALLEVYN Life is an innovative woundcare product which is easy to use for both clinicians and patients. Its' design consists of a number of features and benefits, many of which are a first for the foam dressing category and all designed with the goal of improving outcomes and alleviating the burden on healthcare budgets. These innovations have been achieved whilst maintaining the core attributes of ALLEVYN which customers know and love, and incorporate the findings of the ethnographic research which led to elements including;

  • A unique shape featuring sizes that fit the contours of the human body aiding dressing retention and allowing the patient to feel secure that their dressing will stay in place
  • Materials integrated into the design that provide cushioning and protection from knocks and bumps
  • Low trauma silicone adhesive to provide minimal pain at dressing changes
  • A hyper-absorbent lock away core to prevent leakage of exudate
  • A change indicator to avoid unnecessary dressing changes reducing wastage
  • Masking to prevent patient embarrassment and stigma caused by exudate being obviously visiblethrough the dressing

◊ Trademark of Smith & Nephew


Susan Myers  
Advanced Wound Management +44 (0) 1482 225181
Smith & Nephew  
Charles Reynolds +44 (0)20 7401 7646
Smith & Nephew  
Phil Cowdy +44 (0)20 7401 7646
Smith & Nephew  

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit

Forward-Looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.